Clinical Trials
If you are interested in participating in our research, give us a call at (503)-207-2066 to determine your eligibility.
Current Clinical Research Projects at our Clinic
TauRx Therapeutics Ltd. (LUCIDITY)
Protocol: TRx-237-039
Patients: <90 years old
Diagnostic: MCI/Early Alzheimer’s disease
Agent: Leuco-methylthioninium bis(hydromethanesulfonate) (LMTM)
Daily Oral Administration
Currently Enrolling: No
Athira Pharma Inc. (Act AD)
Protocol: ATH-1017-AD-0202
Patients: 55-85 years old
Diagnostic: Probable Mild-Moderate AD
Agent: ATH-1017
Daily Subcutaneous Injection
Currently Enrolling: Closing Soon
Athira Pharma Inc. (Lift AD)
Protocol: ATH-1017-AD-0201
Patients: 55-85 years old
Diagnostic: Probable Mild-Moderate AD
Agent: ATH-1017
Daily Subcutaneous Injection
Currently Enrolling: No
Eli Lilly and Company (TRAILBLAZER-ALZ2)
Protocol: I5T-MC-AACI
Patients: 60-85 years old
Diagnostic: Prodromal AD or Mild AD Dementia
Agent: Donanemab
Intravenous Administration Every 4 Weeks
Currently Enrolling: Closing Soon
Eli Lilly and Company (TRAILBLAZER-ALZ3)
Protocol: I5T-MC-AACM
Patients: 55-80 years old
Diagnostic: Prodromal AD or Mild AD Dementia
Agent: Donanemab
Intravenous Administration Every 4 Weeks
Currently Enrolling: Awaiting Activation to Begin Enrolling
Website Not Yet Provided
Alzheon Inc. (APOLLOE4)
Protocol: ALZ-801-AD301
Patients: 50-80 years old
Diagnostic: Early Alzheimer’s disease
Agent: ALZ-801
Twice Daily Oral Administration
Currently Enrolling: Yes
Alector Inc. (INVOKE-2)
Protocol: AL002-2
Patients: 50-85 years old
Diagnostic: Early Alzheimer’s disease
Agent: AL002
Intravenous Administration Every 4 Weeks
Currently Enrolling: Awaiting Activation to Begin Enrolling
Novo Nordisk (EVOKE Plus)
Study ID: NN6535-4725
Patients: 55-85 years old
Diagnostic: Early Alzheimer’s disease
Agent: Semaglutide
Once Daily Oral Administration
Currently Enrolling: Awaiting Activation to Begin Enrolling
Novo Nordisk (EVOKE)
Study ID: NN6535-4730
Patients: 55-85 years old
Diagnostic: Early Alzheimer’s disease
Agent: Semaglutide
Once Daily Oral Administration
Currently Enrolling: Awaiting Activation to Begin Enrolling
Biogen (ICARE AD)
Protocol: US-ALZ-11855
Patients: 18 or Older
Diagnostic: AD
Agent: Aducanumab
Intravenous Administration Every 4 Weeks
Currently Enrolling: Awaiting Activation to Begin Enrolling
Website Not Yet Provided
American College of Radiology (New IDEAS)
Study Name: Imaging Dementia-Evidence for Amyloid Scanning Study
Patients: Medicare Beneficiary with Medicare as Primary Insurance
Diagnostic: MCI or Dementia
Study Procedure: PET Scan with Pre- and Post-Scan Clinical Assessments
Currently Enrolling: Awaiting Activation to Begin Enrolling
Eisai (Clarity AD)
Protocol: BAN2401-G000-301
Patients: 50-90 years old
Diagnostic: MCI due to AD/Mild AD
Agent: Monoclonal anti-amyloid antibody
Infusion
Currently Enrolling: No